HC Wainwright reaffirmed their buy rating on shares of Merus Labs International (TSE:MSL – Free Report) (NASDAQ:MSLI) in a research note released on Monday morning, Zacks.com reports. HC Wainwright also issued estimates for Merus Labs International’s Q1 2024 earnings at ($0.05) EPS, Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.23) EPS and FY2028 earnings at ($0.22) EPS.
Merus Labs International Price Performance
Merus Labs International has a 12 month low of C$0.95 and a 12 month high of C$1.76. The stock has a 50 day moving average price of C$1.65.
Merus Labs International (TSE:MSL – Get Free Report) (NASDAQ:MSLI) last announced its quarterly earnings results on Wednesday, March 27th. The specialty pharmaceutical company reported C($0.06) EPS for the quarter, missing analysts’ consensus estimates of C($0.01) by C($0.05).
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Recommended Stories
- Five stocks we like better than Merus Labs International
- The How And Why of Investing in Oil Stocks
- United Airlines Soars on Earnings Beat
- What Are Dividend Contenders? Investing in Dividend Contenders
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Investing in large cap stocks: Diving into big caps
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.